Skip to main content
SpringerLink
Log in

Prognostic factors in chronic lymphocytic leukemia

  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Chronic lymphocytic leukemia (CLL) is truly a heterogenous disease, in which individual outcomes range from no need for therapeutic intervention to very aggressive, nonresponding disease. The ability to develop clear, sound prognostic information that permits reliable counsel must be our goal. A combination of easily obtainable, traditional prognostic parameters (bone marrow infiltration patterns, β-2 microglobulin) along with the clinical Rai stage is still frequently used in the initial risk stratification of patients with CLL. However, novel parameters such as defects detectable on fluorescence in situ hybridization (FISH), expression levels of CD38 and ZAP-70, and immunoglobulin heavy-chain variable region status can add significant prognostic information about a given patient with CLL. How to incorporate these newer tests within the context of the more traditional parameters for a patient with a new diagnosis is the focus of significant continuing research. The outcome of this research has implications for predicting clinical progression rates and the response and duration of response to therapy, as well as for highlighting high-risk patients who will need earlier or more specific treatment approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Morton LM, Wang SS, Devesa SS, et al.: Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 2006, 107:265–276.

    Article  PubMed  CAS  Google Scholar 

  2. Rai KR, Sawitsky A, Cronkite EP, et al.: Clinical staging of chronic lymphocytic leukemia. Blood 1975, 46:219–234.

    PubMed  CAS  Google Scholar 

  3. Binet JL, Auquier A, Dighiero G, et al.: A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981, 48:198–206.

    Article  PubMed  CAS  Google Scholar 

  4. Molica S: Progression and survival studies in early chronic lymphocytic leukemia. Blood 1991, 78:895–899.

    PubMed  CAS  Google Scholar 

  5. Keating MJ, Lerner S, Kantarjian HM, et al.: The serum B2-microglobulin level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia (CLL) [abstract]. Blood 1995, 86:60.

    Google Scholar 

  6. Molica S, Levato D, Cascavilla N, et al.: Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and beta2-microglobulin in B-cell chronic lymphocytic leukemia. Eur J Haematol 1999, 62:117–122.

    Article  PubMed  CAS  Google Scholar 

  7. Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C: Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol 1986, 62:567–575.

    PubMed  CAS  Google Scholar 

  8. Seiler T, Dohner H, Stilgenbauer S: Risk stratification in chronic lymphocytic leukemia. Semin Oncol 2006, 33:186–194.

    Article  PubMed  CAS  Google Scholar 

  9. Magnac C, Porcher R, Davi F, et al.: Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL. Leukemia 2003, 17:133–137.

    Article  PubMed  CAS  Google Scholar 

  10. Matthews C, Catherwood MA, Morris TC, et al.: Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression. Eur J Haematol 2006, 77:309–317.

    Article  PubMed  CAS  Google Scholar 

  11. Wierda WG, O’Brien SM, Wang X, et al.: Models predictive for survival in untreated patients with CLL at initial presentation and initial treatment [abstract]. J Clin Oncol 2005, 23(suppl): 6593.

    Google Scholar 

  12. Deaglio S, Vaisitti T, Aydin S, et al.: In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. Blood 2006, 108:1135–1144.

    Article  PubMed  CAS  Google Scholar 

  13. Shanafelt TD, Geyer SM, Kay NE: Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood 2004, 103:1202–1210.

    Article  PubMed  CAS  Google Scholar 

  14. Ghia P, Guida G, Stella S, et al.: The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 2003, 101:1262–1269.

    Article  PubMed  CAS  Google Scholar 

  15. Gentile M, Mauro FR, Calabrese E, et al.: The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience. Br J Haematol 2005, 130:549–557.

    Article  PubMed  Google Scholar 

  16. Pittner BT, Shanafelt TD, Kay NE, Jelinek DF: CD38 expression levels in chronic lymphocytic leukemia B cells are associated with activation marker expression and differential responses to interferon stimulation. Leukemia 2005, 19:2264–2272.

    Article  PubMed  CAS  Google Scholar 

  17. Zucchetto A, Bomben R, Dal Bo M, et al.: CD49d in B-cell chronic lymphocytic leukemia: correlated expression with CD38 and prognostic relevance [letter]. Leukemia 2006, 20:523–525; author reply 528–529.

    Article  PubMed  CAS  Google Scholar 

  18. Crespo M, Villamor N, Gine E, et al.: ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia. Clin Cancer Res 2006, 12:726–734.

    Article  PubMed  CAS  Google Scholar 

  19. Nolz JC, Tschumper RC, Pittner BT, et al.: ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype. Leukemia 2005, 19:1018–1024.

    Article  PubMed  CAS  Google Scholar 

  20. Chen L, Widhopf G, Huynh L, et al.: Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002, 100:4609–4614.

    Article  PubMed  CAS  Google Scholar 

  21. Crespo M, Bosch F, Villamor N, et al.: ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003, 348:1764–1775.

    Article  PubMed  CAS  Google Scholar 

  22. Rassenti LZ, Huynh L, Toy TL, et al.: ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004, 351:893–901.

    Article  PubMed  CAS  Google Scholar 

  23. Hus I, Podhorecka M, Bojarska-Junak A, et al.: The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia. Ann Oncol 2006, 17:683–690.

    Article  PubMed  CAS  Google Scholar 

  24. Dewald GW, Brockman SR, Paternoster SF, et al.: Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol 2003, 121:287–295.

    Article  PubMed  Google Scholar 

  25. Dohner H, Stilgenbauer S, Benner A, et al.: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000, 343:1910–1916.

    Article  PubMed  CAS  Google Scholar 

  26. Byrd JC, Gribben JG, Peterson BL, et al.: Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 2006, 24:437–443.

    Article  PubMed  CAS  Google Scholar 

  27. Dickinson JD, Gilmore J, Iqbal J, et al.: 11q22.3 deletion in B-chronic lymphocytic leukemia is specifically associated with bulky lymphadenopathy and ZAP-70 expression but not reduced expression of adhesion/cell surface receptor molecules. Leuk Lymphoma 2006, 47:231–244.

    Article  PubMed  CAS  Google Scholar 

  28. Dickinson JD, Joshi A, Iqbal J, et al.: Genomic abnormalities in chronic lymphocytic leukemia influence gene expression by a gene dosage effect. Int J Mol Med 2006, 17:769–778.

    PubMed  CAS  Google Scholar 

  29. Stilgenbauer S, Lichter P, Dohner H: Genetic features of B-cell chronic lymphocytic leukemia. Rev Clin Exp Hematol 2000, 4:48–72.

    Article  PubMed  CAS  Google Scholar 

  30. Fink SR, Smoley SA, Stockero KJ, et al.: Loss of TP53 is due to rearrangements involving chromosome region 17p10∼p12 in chronic lymphocytic leukemia. Cancer Genet Cytogenet 2006, 167:177–181.

    Article  PubMed  CAS  Google Scholar 

  31. Lozanski G, Heerema NA, Flinn IW, et al.: Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004, 103:3278–3281.

    Article  PubMed  CAS  Google Scholar 

  32. Stilgenbauer S, Kröber A, Busch R, et al.: 17p deletion predicts for inferior overall survival after fludarabine-based first line therapy in chronic lymphocytic leukemia: first analysis of genetics in the CLL4 trial of the GCLLSG [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:212a. Abstract 715.

    Google Scholar 

  33. Shanafelt TD, Witzig TE, Fink SR, et al.: Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol 2006, 24:4634–4641.

    Article  PubMed  Google Scholar 

  34. Dicker F, Schnittger S, Haferlach T, et al.: Immunostimulatory oligonucleotide-induced metaphase cytogenetics detects chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status and CD38 expression. Blood 2006, 108:3152–3160.

    Article  PubMed  CAS  Google Scholar 

  35. Mayr C, Speicher MR, Kofler DM, et al.: Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 2006, 107:742–751.

    Article  PubMed  CAS  Google Scholar 

  36. Hamblin TJ, Davis Z, Gardiner A, et al.: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999, 94:1848–1854.

    PubMed  CAS  Google Scholar 

  37. Damle RN, Wasil T, Fais F, et al.: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999, 94:1840–1847.

    PubMed  CAS  Google Scholar 

  38. Thorselius M, Krober A, Murray F, et al.: Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood 2006, 107:2889–2894.

    Article  PubMed  CAS  Google Scholar 

  39. Tobin G, Rosen A, Rosenquist R: What is the current evidence for antigen involvement in the development of chronic lymphocytic leukemia? Hematol Oncol 2006, 24:7–13.

    Article  PubMed  CAS  Google Scholar 

  40. Capello D, Zucchetto A, Degan M, et al.: Immunophenotypic characterization of IgV(H)3-72 B-cell chronic lymphocytic leukaemia (B-CLL). Leuk Res 2006, 30:1197–1199.

    PubMed  CAS  Google Scholar 

  41. Degan M, Bomben R, Dal Bo M, et al.: Analysis of IgV gene mutations in B cell chronic lymphocytic leukaemia according to antigen-driven selection identifies subgroups with different prognosis and usage of the canonical somatic hypermutation machinery. Br J Haematol 2004, 126:29–42.

    Article  PubMed  CAS  Google Scholar 

  42. Jelinek DF, Tschumper RC, Geyer SM, et al.: Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol 2001, 115:854–861.

    Article  PubMed  CAS  Google Scholar 

  43. Ritgen M, Lange A, Stilgenbauer S, et al.: Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 2003, 101:2049–2053.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mayo Clinic, Stabile 6-28, 200 First Street SW, Rochester, MN, 55905, USA

    Neil E. Kay MD

Authors
  1. Neil E. Kay MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tait D. Shanafelt MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Neil E. Kay MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kay, N.E., Shanafelt, T.D. Prognostic factors in chronic lymphocytic leukemia. Curr Hematol Malig Rep 2, 49–55 (2007). https://doi.org/10.1007/s11899-007-0007-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-007-0007-1

Keywords

Search

Navigation